Q1 Earnings Estimate for Prime Medicine Issued By Wedbush

Prime Medicine, Inc. (NYSE:PRME) – Wedbush issued their Q1 2026 EPS estimates for Prime Medicine in a research note issued on Thursday, May 8th. Wedbush analyst D. Nierengarten forecasts that the company will post earnings per share of ($0.38) for the quarter. Wedbush currently has a “Outperform” rating and a $13.00 price target on the stock. The consensus estimate for Prime Medicine’s current full-year earnings is ($1.68) per share. Wedbush also issued estimates for Prime Medicine’s Q2 2026 earnings at ($0.38) EPS, Q3 2026 earnings at ($0.36) EPS and Q4 2026 earnings at ($0.35) EPS.

Prime Medicine (NYSE:PRME) last announced its quarterly earnings data on Friday, March 7th. The company reported ($1.65) earnings per share for the quarter. During the same period in the prior year, the business earned ($2.18) earnings per share.

A number of other equities analysts also recently commented on PRME. Chardan Capital raised their price objective on shares of Prime Medicine from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, March 20th. StockNews.com raised Prime Medicine to a “sell” rating in a report on Tuesday, February 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Prime Medicine in a research note on Wednesday, March 19th. One analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.83.

Prime Medicine Price Performance

PRME opened at $1.27 on Monday. The company has a market capitalization of $166.57 million, a P/E ratio of -0.62 and a beta of 1.90. The firm’s fifty day moving average price is $1.62 and its two-hundred day moving average price is $2.57. Prime Medicine has a fifty-two week low of $1.12 and a fifty-two week high of $8.27.

Hedge Funds Weigh In On Prime Medicine

Institutional investors have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. grew its stake in Prime Medicine by 4.5% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,977,828 shares of the company’s stock worth $11,616,000 after buying an additional 170,541 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Prime Medicine by 2.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,584,476 shares of the company’s stock worth $4,628,000 after acquiring an additional 38,515 shares during the last quarter. Geode Capital Management LLC increased its holdings in Prime Medicine by 7.9% during the 4th quarter. Geode Capital Management LLC now owns 1,467,606 shares of the company’s stock valued at $4,287,000 after purchasing an additional 107,627 shares in the last quarter. Westwood Holdings Group Inc. raised its position in Prime Medicine by 96.5% in the 4th quarter. Westwood Holdings Group Inc. now owns 883,129 shares of the company’s stock valued at $2,579,000 after purchasing an additional 433,653 shares during the last quarter. Finally, Greenwich Wealth Management LLC boosted its stake in Prime Medicine by 5.6% in the fourth quarter. Greenwich Wealth Management LLC now owns 774,001 shares of the company’s stock worth $2,260,000 after purchasing an additional 41,000 shares in the last quarter. 70.37% of the stock is owned by institutional investors.

About Prime Medicine

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.